 "Caplin Point Labs zooms over 40% in six days on strong Q4 results")
Caplin Point Laboratories hit new high of Rs 574, up 7% on BSE in otherwise weak market, extending its past one week rally, after the company reported more than doubled consolidated net profit of Rs 33 crore in March quarter (Q4FY17), on the back of strong revenue growth. The pharmaceutical company had reported profit of Rs 16 crore in the same quarter a year ago.
Gross revenues during the quarter under review increased by 47% to Rs 121 crore against Rs 82 crore in the corresponding quarter of previous fiscal. Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 40% from 27% in Q4FY16.
The company on May 8 said it has received the Establishment Inspection Report from the US health regulator for its Gummidopoondi facility in Chennai.
“Caplin Point has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for inspection carried out during October 21-27, 2016, at its sterile injectable plant at Gummidopoondi in Tamil Nadu,” Caplin Point Laboratories said in a filing to the BSE.
“This will pave the way for our entry into the largest pharma market in the world,” Caplin Point Laboratories Chairman C C Paarthipan said.
In past six trading sessions, the stock rallied 41% from Rs 406 on May 10, against 1% rise in the S&P BSE Sensex.
At 1:41 pm; the stock was up 6% to Rs 567 on BSE, as compared to 0.40% decline in the benchmark index. A combined 695,176 shares changed hands on the counter on BSE and NSE.
Gross revenues during the quarter under review increased by 47% to Rs 121 crore against Rs 82 crore in the corresponding quarter of previous fiscal. Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 40% from 27% in Q4FY16.
The company on May 8 said it has received the Establishment Inspection Report from the US health regulator for its Gummidopoondi facility in Chennai.
“Caplin Point has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for inspection carried out during October 21-27, 2016, at its sterile injectable plant at Gummidopoondi in Tamil Nadu,” Caplin Point Laboratories said in a filing to the BSE.
“This will pave the way for our entry into the largest pharma market in the world,” Caplin Point Laboratories Chairman C C Paarthipan said.
In past six trading sessions, the stock rallied 41% from Rs 406 on May 10, against 1% rise in the S&P BSE Sensex.
At 1:41 pm; the stock was up 6% to Rs 567 on BSE, as compared to 0.40% decline in the benchmark index. A combined 695,176 shares changed hands on the counter on BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%